Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Custodiol vs Blood Cardioplegia in Pediatric Cardiac Surgery
NCT03082716Phase 2Completed
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of HTK Custodiol in congenital heart disease (CHD) (2 arms), sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoints: Mortality at 30 days, Length of ICU stay at 90 days and 1 more. Started Mar 2016; status: completed.
02
Drugs
HTK Custodiol
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT03082716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082716.